In vitro metabolic characterization of the SARS-CoV-2 papain-like protease inhibitors GRL0617 and HY-17542

The SARS-CoV-2 pandemic requires a new therapeutic target for viral infection, and papain-like protease (Plpro) has been suggested as a druggable target. This in-vitro study was conducted to examine the drug metabolism of the GRL0617 and HY-17542, Plpro inhibitors. Metabolism of these inhibitors was...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Hyunki, Kim, Young Jun, Chae, Jung-Woo, Meyer, Markus R., Kim, Sang Kyum, Ryu, Chang Seon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975351/
https://www.ncbi.nlm.nih.gov/pubmed/36874001
http://dx.doi.org/10.3389/fphar.2023.1067408

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9975351/
https://www.ncbi.nlm.nih.gov/pubmed/36874001
http://dx.doi.org/10.3389/fphar.2023.1067408

Ejemplares similares